Related Experiment Video
Updated: Mar 29, 2026
07:51
Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
Published on: February 17, 2023
1.6K
Serelaxin and acute heart failure.
Jeremy Tietjens1, John R Teerlink2
1School of Medicine, University of California San Francisco, San Francisco, California, USA.
Heart (British Cardiac Society)
|November 26, 2015
Summary
Serelaxin, a novel therapeutic agent, shows promise for acute heart failure (AHF) treatment. Clinical trials indicate it improves symptoms, reduces hospital stays, and increases survival rates in AHF patients.
Area of Science:
- Cardiology
- Pharmacology
- Endocrinology
Background:
- Developing novel treatments for acute heart failure (AHF) has faced significant challenges.
- Relaxin, a human peptide hormone, influences hemodynamic adaptations during pregnancy.
- Serelaxin, a recombinant human relaxin-2, is being investigated for AHF treatment.
Purpose of the Study:
- To review the physiological function and mechanism of action of serelaxin.
- To present clinical trial results for serelaxin in AHF patients.
- To discuss future directions for serelaxin in AHF therapy.
Main Methods:
- Review of physiological effects and mechanism of action of serelaxin.
- Analysis of data from a 1161-patient, placebo-controlled Phase III trial (RELAX-AHF).
- Inclusion of ongoing Phase III trials (RELAX-AHF-2; RELAX-AHF-ASIA).
Main Results:
- Serelaxin demonstrated beneficial hemodynamic effects, including decreased pulmonary and systemic resistance and increased renal blood flow.
- The RELAX-AHF trial showed significant improvements in AHF symptoms and reduced worsening of heart failure.
- Serelaxin treatment led to decreased hospital length of stay and increased 180-day survival post-hospitalization.
Conclusions:
- Serelaxin exhibits a favorable safety and efficacy profile for AHF treatment.
- Further trials are ongoing to confirm and expand upon these findings.
- Serelaxin represents a potential new therapeutic option for patients suffering from acute heart failure.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.3K
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
7.0K
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
01:29Heart Failure II: Pathophysiology
1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
01:30Heart Failure V: Medical Management
520
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
520
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:26Heart Failure Drugs: Inotropic Agents
1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K